The Efficacy of Pasteurised Akkermansia Muciniphila in Healthy Medical Workers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

202 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-24

Study Completion Date

2025-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gut microbiota alterations secondary to chronic stress might serve as a triggering factor towards manifestation of somatic and mental symptoms. The administration of pasteurised A. muciniphila MucT has the capability of supporting microbiota and improving the gut barrier integrity, which might lead to decrease of inflammation and the negative health consequences of stress in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Akkermansia and Weight Maintenance

NCT05417360

Obesity Microtia Metabolic Syndrome +1 more

COMPLETED NA

Probiotics, Immunity, Stress, and QofL

NCT05063305

Stress Quality of Life

COMPLETED NA

The Effect of Probiotic Supplementation on Mental Health in Healthy Volunteers

NCT06391216

Healthy Stress-related Problem Depression +1 more

COMPLETED NA

Weight Loss Effect of Akkermansia Muciniphila in Obese Patients

NCT06780007

28≤BMI≤35Kg/m2

COMPLETED NA

Study on the Effects of a Probiotic on Autonomic and Psychological Stress

NCT02417454

Stress, Psychological

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Gut-brain-microbiota axis (GBMA) is a bi-directional pathway, both neuronal and biochemical, between the intestine and the Central Nervous System (CNS). The gut microbiota plays a central role in gut-brain communication. The composition of intestinal microbiota and its functions play an important role in the pathogenesis of disorders of gut-brain interaction - both within the digestive tract and in the brain.

Modulation of gut microbiota with the aid of probiotics, antibiotics, or germ-free feeding protocols significantly altered stressful event-induced behavioral outcomes in rodents. Moreover, the intake of various probiotics significantly improved stress-induced anxiety and depressive-like behaviors in mice. In humans, probiotics were also documented to display some beneficial effects on mental health, including alteration of emotional bias in healthy individuals, and alleviating stress and anxiety among stressed adults.

Psychobiotics are imposed with certain limitations related to their standardization and end-shelf-life product stability. Therefore, the use of postbiotics, which contain bacterial metabolites or other bacteria derived fragments are viewed as novel solutions and alternatives to use of standard probiotics. One of novel postbiotics of interest among scientists and clinicians is pasteurized Akkermansia muciniphila MucT (PAM).

Animal studies indicate that administration of Akkermansia muciniphila can ameliorate metabolic syndrome, obesity, diabetes, and inflammatory bowel disease in animals and has psychobiotic potential. Similar to live A. muciniphila, PAM could ameliorate several diseases as well. The mechanism of action of PAM - improving gut barrier integrity - suggests the potential use to reduce the negative effects of stress. Human studies shown that PAM is safety, what was confirmed in the Scientific Opinion of EFSA. Recently A. muciniphila was approved as the Novel Food.

A proof of concept study will be conducted to verify the hypothesis that PAM reduces the psychological and somatic effects of stress.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Healthy Dietary Supplement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

parallel-groups, randomized, placebo-controlled clinical study

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Sequentially numbered drug containers of identical appearance

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pasteurized Akkermansia muciniphila

pasteurized A.muciniphila (Pasteurized, 3x10\^10 bacteria per day) as supplement for 3 months,

Group Type EXPERIMENTAL

Pasteurized Akkermansia muciniphila

Intervention Type DIETARY_SUPPLEMENT

PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach

Placebo

placebo administered for 3 months once a day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pasteurized Akkermansia muciniphila

PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach

Intervention Type DIETARY_SUPPLEMENT

Placebo

PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PAM PBO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Working in a high stress hospital department, like: emergency, trauma, intensive care, surgery, internal diseases;
* Written informed consent to participate in this study before any study-mandated procedure;
* Body mass index (BMI) ≥18.5 kg/m2 and ≤ 35 kg/m2;
* A willingness and motivation to follow the study protocol.

Exclusion Criteria

* Diagnosis of autoimmune, neurological, immunocompromised, thyroid, inflammatory bowel diseases, irritable bowel syndrome, diabetes, cancer, and/or IgE-dependent allergy;
* Psychiatric comorbidities, including mental retardation, organic brain dysfunction, or addiction (except nicotine and caffeine), intake of antipsychotic and antidepressive drugs;
* Proton pump inhibitors usage;
* The use of antibiotics and/or probiotics 4 weeks prior to the study;
* Glucocorticosteroids and/or metformin treatment;
* Dietary supplementation (except for vitamin D) within the three months before screening;
* Specific restrictive (e.g. elimination, vegan, FODMAP, reduction) diet within the three months before screening;
* Significant changes in physical activity 4 weeks before the trial entry;
* Pregnancy or lactation;
* Significant GI surgery within the last 6 months prior to or planned during the study;
* Any other medication for management of IBS complaints like peppermint oil, bile acid binders;
* Lactose intolerance;
* Participation in another study during the last 30 days prior to and during the study;
* Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes